FGP
ROIV icon

Freestone Grove Partners’s Roivant Sciences ROIV Stock Holding History

Freestone Grove Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,515
Closed -$355K – 875
2025
Q2 		$355K Buy
+31,515
New +$342K ﹤0.01% 572

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Freestone Grove Partners's ROIV Position: Q3 2025 in Review

Freestone Grove Partners sold out of Roivant Sciences (ROIV) in Q3 2025, closing a stake of 31,515 shares — an estimated $355K sold.

Freestone Grove Partners first reported a position in ROIV in Q2 2025 and held it in 1 quarter. The position peaked at $355K in Q2 2025. 337 funds tracked by Wall St. Rank hold ROIV as of Q3 2025.

  • Freestone Grove Partners reported no remaining Roivant Sciences position as of Q3 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 31,515 Roivant Sciences shares in Q3 2025, an estimated $355K.
  • Freestone Grove Partners first reported a position in Roivant Sciences in Q2 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Roivant Sciences position peaked at $355K in Q2 2025.
  • 337 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2025.

Based on Freestone Grove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.